Lupus and Left Ventricular Assist Devices: High-Risk for Bleeding?

Journal Article (Journal Article)

Continuous-flow left ventricular assist devices (LVAD) have become an increasingly utilized treatment strategy for patients with end-stage heart failure. Despite the improved outcomes evident with current generation pumps, proper patient selection remains crucial to minimize the risk of potential adverse events. The evolving use of these devices as destination therapy (DT) has led to growing numbers of patients with higher risk comorbid conditions being evaluated as potential LVAD candidates. Understanding which patient and disease-specific characteristics increase postoperative morbidity and mortality is paramount as this technology continues to expand and the experience with select populations remains limited. Presented here is a case of a patient with systemic lupus erythematosus receiving a HeartWare LVAD as DT complicated by recurrent, diffuse spontaneous bleeding. The case presented here highlights a potential unique bleeding complication in a high-risk patient cohort and underscores the need to enhance our understanding of factors influencing outcomes in high-risk populations after LVAD therapy.

Full Text

Duke Authors

Cited Authors

  • Gage, A; Blumer, V; Joyce, E

Published Date

  • November 2019

Published In

Volume / Issue

  • 65 / 8

Start / End Page

  • e95 - e96

PubMed ID

  • 30640183

Electronic International Standard Serial Number (EISSN)

  • 1538-943X

International Standard Serial Number (ISSN)

  • 1058-2916

Digital Object Identifier (DOI)

  • 10.1097/mat.0000000000000946


  • eng